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The aim of this paper is to report on the challenges associated with identifying disease recurrence following combined modality
therapy (CMT) for primary lymphoma of the tibia in which an intramedullary nail has been placed. A patient with primary bone
lymphoma (PBL) was treated with CMT (chemotherapy and radiation therapy). After a complete response, he has been followed
for eighteen months by physical exam and radiographic imaging. Despite persistent increased tracer accumulation at the original
site, he has no proven recurrence. Literature review showed a small number of retrospective, single institution reviews detailing
clinical experience and expected outcome in patients treated with PBL limited to one bony site of disease. PBL presents a treatment
challenge, particularly when a weight-bearing long bone is diﬀusely involved and followup is complicated after placement of
stabilizing hardware. Close coordination of the oncology team and diagnostic radiology is required to ensure optimal outcome.
1.Introduction
Primary bone lymphoma (PBL) is an uncommon disease
that accounts for approximately 3% of all primary bone
malignancies and 5% of all extranodal non-Hodgkin’s lym-
phoma cases [1]. The most common histologic subtype is
diﬀuse large B-cell lymphoma (DLBCL), with a reported
frequency that ranges from 66.3% of patients with PBL
in a recent analysis of the Surveillance, Epidemiology, and
End Results (SEER) database [2] to as high as 80–91%
in other retrospective reviews [3–5]. The most common
presenting symptom is bone pain, followed by pathologic
fracture, palpable mass, and systemic “B” symptoms (fever,
weight loss, and night sweats) [3, 5]. PBL is staged using
the Ann Arbor classiﬁcation that was originally developed
for staging Hodgkin’s disease [6]. However, when outcomes
were reviewed for patients with aggressive (intermediate
or high grade) non-Hodgkin’s lymphoma, the Ann Arbor
staging system could not distinguish between patients with
f a v o r a b l ev e r s u su n f a v o r a b l ep r o g n o s e s[ 7]. As a result,
the International Prognostic Index (IPI) [8] was developed
to predict long-term survival in patients with aggressive
non-Hodgkin’s lymphoma. The IPI classiﬁes patients into
one of four risk categories based on age, serum lactate
dehydrogenase (LDH), performance status, tumor stage,
and number of involved extranodal sites [8]. Potential
treatment options based on the stage and IPI score are
R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) for 3 cycles plus involved ﬁeld
radiation therapy (IFRT) or R-CHOP for 6 to 8 cycles2 Case Reports in Oncological Medicine
plus or minus IFRT [9]. Two recent randomized trials of
systemic chemotherapy options for patients with DLBCL
have speciﬁed adjuvant radiation therapy to sites of bulky
or extranodal disease (RICOVER-60 and MinT) after the
completion of chemotherapy [10, 11].
2.MaterialsandMethods
Written informed consent was obtained from the subject
who has approved this document for print, electronic
publication, and reprinting in foreign editions. He has been
given the opportunity to see this paper in its entirety.
The patient is a 49-year-old male who presented with
left leg pain along the lateral calf that started after running.
He was initially diagnosed with shin splints and managed
conservatively with physical therapy for two months but
his symptoms did not improve. After failure of conservative
therapy, he was referred for further workup. A bone scan
of his lower extremities was consistent with a stress fracture
of the left tibia. Treatment with steroids improved his
pain temporarily, but the pain returned after several weeks
and became progressively worse. An MRI of his left lower
extremity demonstrated scattered small lucencies along the
midtibial diaphysis with associated cortical thickening and
periosteal reaction but no soft tissue mass. His blood work
showed an ESR of 17mm/hr, a CRP of 10.6mg/L, an LDH
of 128units/L, and a white blood cell count of 4.8 × 103/µL.
An open biopsy of the left tibial bone was consistent with
chronic inﬂammation only, with no evidence of malignancy
or infection.
After consultation with infectious disease, the patient
was treated with antibiotics for what was thought to be
osteomyelitis. This initially relieved his symptoms. After
he completed his antibiotic course, his pain and swelling
returned. A second open biopsy was performed by an
orthopedic oncologist during which an area of spongy bone
was resected and identiﬁed as germinal center DLBCL. An
intramedullary (IM) nail with cortical/cancellous bone allo-
graft was placed following the biopsy to prevent pathologic
fracture due to the large amount of bone removed. Staging
studies done prior to placement of the IM nail, including a
skeletalsurveyandCTofthechest,abdomenandpelvis,were
all negative for any additional lesions. A bone scan, [18F]
ﬂuoro-2-deoxy-d-glucose (FDG) positron emission tomog-
raphy (PET)/CT, and bone marrow biopsy were completed
and were also negative for involvement outside the original
left tibial lesion, and he was staged as IAE DLBCL [6].
Activity in the patellar region of the initial PET/CT scan was
thought to be related to the surgical intervention (Figure 1).
Based on the patient’s stage and IPI score of 0, he would have
a predicted 5-year survival of between 83 and 90% [8, 12],
and his recommended treatment would be R-CHOP for 3
cycles followed by IFRT [9]. Following the third cycle of R-
CHOP, the patient was judged to have a complete response
based on a repeat PET/CT. The patient elected to continue
with the treatment course as recommended by the National
Comprehensive Cancer Network (NCCN) clinical guidelines
[9] and presented to Radiation Oncology for consideration
of consolidation radiation therapy. A CT planning study
was completed with the patient in the supine position with
an alpha cradle for positioning and placement. The CT
simulation was fused with his initial PET/CT scan and used
to plan his radiation. We elected to treat the entire length
of the tibia as the involved ﬁeld, due to the diﬀuse nature
of the disease on the pretreatment imaging (Figure 1)a n d
the apparent involvement of the marrow space. Treating the
entirelengthofthelefttibiawasproblematicinthateitheran
AP/PAoropposedlateralﬁeldarrangementwouldinvariably
treat the limb circumferentially with an associated long-term
risk of limb edema. To limit this risk, IMRT was utilized in
order to preferentially spare the posterior compartment of
his left lower leg. He was treated via Tomotherapy to the
entire tibia with 200cGy fractions to a total of 4400cGy
(Figure 2) and was able to complete his radiation therapy
without any treatment breaks. A posttreatment PET/CT scan
showed no residual activity (Figure 3).
After completion of his radiation treatments, the plan
was to continue following the patient with serial labs and
imaging to monitor for disease recurrence. A subsequent
PET/CT scan, three months after completion of radiation
therapy, showed no evidence of focal activity at the site of
originaldiseaseoratanydistantsite.SerumLDHatthistime
was also normal at 324units/L. An MRI showed no evidence
of residual disease; however, the exam was limited by metal
artifact from the IM nail. The CT portion of the PET/CT
studies also had signiﬁcant artifact and in conjunction with
Radiology, the decision was made to continue following the
patient with serial PET/CT scans only.
A subsequent PET/CT scan, nine months after com-
pletion of radiation therapy, showed increasing metabolic
activity at the previous site of disease (Figure 4). A CT
guided needle biopsy of the area was done initially that was
nondiagnostic. An open biopsy was then performed, again,
by an orthopedic oncologist, that also showed no evidence
of malignancy. A CT scan of the left lower extremity taken
after the open biopsy conﬁrmed that the focus of increased
18F FDG accumulation was appropriately biopsied and that
the biopsy area was adequate. Due to the two negative
biopsies, the oncology team recommended followup after
three months with physical exam and repeat PET/CT.
His next PET/CT scan, 13 months following radiation
therapy, again showed the area of increased glucose
metabolism at the medial aspect of the left midtibial shaft
with subtle increase in size and metabolic activity with
standardized uptake value (SUV) of 3.3 compared to 3.1
previously. LDH at this time continued to be within normal
limits. A second open biopsy of the left tibia was performed
that showed only viable bone and necrotic inﬂammatory
debris with no evidence of malignancy. Repeat PET/CT
scans, labs, and physical exams, most recently nearly
two years after completion of combined modality therapy
(CMT),havecontinued toshow onlytheoneareaof elevated
18F FDG activity near his original site of disease with no
evidence of distant failure (Figure 5). The level of elevated
activity has been decreasing slowly and his LDH remains
within normal limits.Case Reports in Oncological Medicine 3
Figure 1: Pretreatment planar PET/CT image.
Figure 2: Tomotherapy planning study images demonstrating dose
distribution and relative sparing of posterior compartment.
3. Results andDiscussion
Due to the scarcity of patients with PBL, no randomized
trials exist to evaluate treatment options. Radiation therapy
was the standard of care for PBL beginning in the 1960s
[13]. Radiation alone provided good local control; however,
asmanyas50%ofpatientstreatedwithradiationalonefailed
systemically with regional or distant metastases [13, 14].
Several retrospective reviews published within the last ﬁve
years have demonstrated improved outcomes with the use
of combined treatment of multiple agent chemotherapy and
radiotherapy [3–5, 15, 16].
Beal et al. reported on a single institution experience and
identiﬁed 82 patients diagnosed and treated with PBL
between 1963 and 2003 [3]. Of the 82 patients, 46 received
a combination of chemotherapy and radiation, 11 received
radiation alone, and 24 received chemotherapy alone. Anal-
ysis of outcomes showed a signiﬁcant improvement with
CMT. Chemotherapy was given in the form of CHOP or R-
CHOP. For the patients who received radiation, either alone
or following chemotherapy, the median dose was 4400cGy.
The reported 5-year overall survival for patients treated with
combined modality versus single modality treatment was
95% versus 78%.
In a retrospective review, Dubey et al. reported on their
experience treating 45 patients with stage IE and IIE PBL
between 1967 and 1992 [17]. Of the 45 patients, 36 were
treated with CMT, 5 were treated with radiation alone,
and 4 were treated with chemotherapy alone. Patients who
received radiation were treated with doses between 4000 and
6000cGy. Among the patients who received CMT, no local
failures were reported with doses of 4400–4600cGy, and
the writers concluded that doses in the range of 4600cGy
allow for optimal local control with acceptable rates of
complication.
Christie et al. recently reported on a prospective study
to evaluate limited chemotherapy and radiotherapy for PBL
[18]. Treatment included 3 cycles of CHOP followed by
radiation to a dose of 4500cGy using a shrinking ﬁeld
technique. The ﬁve-year local control rate was 72% with 9
local failures among the 31 patients included in the study.
Thenumberoflocalfailuresledthemtoconcludethathigher
doses of radiotherapy (4000–4500cGy) should be used to
treat PBL than those usually prescribed for lymphoma in
other tissues.
Baar et al. reported on a series of patients treated for
PBL at a single institution and described the diﬃculty
with assessment of treatment response based on persistent
abnormalities on imaging after treatment [19]. Those abnor-
malitiesarethoughttorepresentboneremodelingorﬁbrosis.
Placement of hardware within the bone to stabilize it can
further complicate assessment of CT scans and MRIs via the
artifact created by the metal rod.4 Case Reports in Oncological Medicine
Figure 3: Postchemotherapy and radiotherapy planar PET/CT image.
Figure 4: Posttreatment planar PET/CT image demonstrating recurrence of PET-avidity at site of original disease.
The Rare Cancer Network recently reported on a mul-
ticenter retrospective review of 116 patients with stages I
and II PBL that looked at prognostic factors and patient
outcomes [20]. Important prognostic factors were identiﬁed
as age, IPI score, complete response, chemotherapy, number
of chemotherapy cycles, and radiation dose. Based on their
analyses, PBL treated with CMT that included radiation
doses of greater than 4000cGy and at least six cycles of
chemotherapy was associated with improved outcomes. The
local control rate was 92% with median followup of 41
months.
The patient in this report had a complete response to
chemotherapy. Three months after completion of his radi-
ation, the PET/CT scan continued to show no evidence
of local recurrence or distant failure. However, an MRI
completed following radiation therapy demonstrated the
challenges associated with monitoring for disease recurrence
in cases where hardware must be placed to prevent patho-
logic fractures. As previously noted, the posttreatment MRI
and CT scans both demonstrated signiﬁcant artifacts caused
by the IM titanium rod that interfered with interpretation
of changes and limited their usefulness as surveillance tools.
Therefore, the decision was made to limit surveillance
imaging to PET/CT scans.
Nine months after completing his chemotherapy and
radiation treatments, a PET/CT scan began to show a focal
lyticlesionintheleftmidtibiacortexwithincreased18FFDG
uptake near the site of original disease. Initially, both a CTCase Reports in Oncological Medicine 5
Figure 5: Postrebiopsy planar PET/CT image demonstrating no evidence of contiguous spread nor systemic recurrence.
guided needle biopsy and open biopsy were both negative for
disease recurrence. Serial PET/CT scans since that time have
shown gradual increase in the size and activity of the lesion.
However, the lesion was not deﬁnitive for recurrence and
could represent posttreatment changes in the bone. 18F FDG
accumulationinnecroticbonehasbeenpreviouslydescribed
[21, 22]. A third biopsy, this time another open biopsy,
again failed to show any malignant cells. Following the third
negative biopsy, the orthopedic surgeon recommended to
the oncology team against any additional sampling to avoid
further weakening of the bone.
In the case of biopsy-proven disease relapse or distant
failure, the next recommended treatment would be high-
dose chemotherapy with autologous stem cell transplant.
However, in the absence of deﬁnitive evidence of local or
distant failure and with the repeated negative biopsies, the
current plan is to continue surveillance and repeat PET/CT
every 3 months.
4. Conclusion
The optimal treatment of PBL appears to be CMT, with
systemic chemotherapy followed by IFRT to a dose in the
range of 4400cGy. Treatment of the entire length of a bone
is diﬃcult with traditional ﬁeld arrangements, and IMRT
is useful to limit the risk of distal extremity lymphedema.
Assessment of local disease control is complicated by bone
remodeling and the potential for artifact due to stabilizing
hardware. Careful coordination with all members of the
oncology team, nuclear medicine, and radiology is essential
for optimal outcomes.
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